Cisplatin Exposure Dysregulates Insulin Secretion in Male and Female Mice
Diabetes · 01.04.2025 · 74 (4) · 528-543
DOI: 10.2337/db24-0419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 14.01.2025. Verfasst von Lahari Basu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Cisplatin, Insulin Secretion, Insulin-Secreting Cells, Insulin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Canadian Institutes of Health Research/Breakthrough T1D/Diabetes Canada, CIHR, Diabetes Canada.
Abstract (Originalsprache)
Cancer survivors have an increased risk of developing type 2 diabetes compared with the general population. Patients treated with cisplatin, a common chemotherapeutic agent, are more likely to develop metabolic syndrome and type 2 diabetes than age- and sex-matched control patients. Surprisingly, the impact of cisplatin on pancreatic islets has not been reported. Our study aimed to determine whether mouse islet function is adversely affected by systemic (in vivo) or direct (in vitro) exposure to cisplatin. In vivo cisplatin exposure led to deficits in glucose-stimulated plasma insulin levels in both male and female mice, despite no differences in glucose tolerance. In vitro cisplatin exposure to mouse islets dysregulated insulin release and reduced oxygen consumption in a non–sex-specific manner. When shifting our focus to male mouse islets, cisplatin altered the expression of genes related to insulin production, oxidative stress, and the Bcl-2 family as early as 6 h postexposure. Genome-wide expression analysis confirmed the pronounced downregulation of genes within the insulin secretion pathway in cisplatin-exposed mouse islets. Data from three human organ donors confirmed that the detrimental effects of cisplatin on insulin secretion and gene expression are reproduced in human islets. Our findings indicate that cisplatin exposure causes significant defects in insulin secretion and may have lasting effects on islet health. Article Highlights Cancer survivors who receive cisplatin chemotherapy have an increased risk of type 2 diabetes, but the underlying mechanisms remain unclear. The aim of this study was to investigate whether cisplatin impacts β-cell health and function, thereby contributing to increased type 2 diabetes risk in cancer survivors. In vivo and in vitro cisplatin exposure dysregulated insulin secretion in male and female mice. In vitro cisplatin exposure reduced oxygen consumption, impaired β-cell exocytotic capacity, and altered expression of genes within the insulin secretion pathway in mouse islets. Understanding how chemotherapeutic drugs cause β-cell injury is critical for designing targeted interventions to reduce the risk of cancer survivors developing type 2 diabetes after treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
- Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada.
- Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
ORCID-Profile: Jennifer E Bruin
Förderung
- Canadian Institutes of Health Research/Breakthrough T1D/Diabetes Canada
- CIHR
- Diabetes Canada
- Natural Sciences and Engineering Research Council of Canada
- Canadian Foundation for Innovation
- Canadian Institutes of Health Research
Zitieren
APA
Basu, L., Grieco-St-Pierre, L., Ching, M. E. A., Stead, J. D. H., Hanson, A. A., Palaniyandi, J., van Zyl, E., Hoyeck, M. P., McKay, K. S., van Allen, K. A., Lee, H., Dai, X. Q., Bautista, A., Fadzeyeva, E., Mulvihill, E. E., Yauk, C. L., Mennigen, J. A., MacDonald, P. E., & Bruin, J. E. (2025). Cisplatin Exposure Dysregulates Insulin Secretion in Male and Female Mice. Diabetes, 74(4), 528-543. https://doi.org/10.2337/db24-0419
Vancouver
Basu L, Grieco-St-Pierre L, Ching MEA, Stead JDH, Hanson AA, Palaniyandi J, et al. Cisplatin Exposure Dysregulates Insulin Secretion in Male and Female Mice. Diabetes. 2025;74(4):528-543. doi:10.2337/db24-0419
BibTeX
@article{Basu2025,
author = {Basu, Lahari and Grieco-St-Pierre, Lili and Ching, Ma Enrica Angela and Stead, John D H and Hanson, Antonio A and Palaniyandi, Jana and van Zyl, Erin and Hoyeck, Myriam P and McKay, Kelsea S and van Allen, Kyle A and Lee, Hyojin and Dai, Xiao-Qing and Bautista, Austin and Fadzeyeva, Evgenia and Mulvihill, Erin E and Yauk, Carole L and Mennigen, Jan A and MacDonald, Patrick E and Bruin, Jennifer E},
title = {Cisplatin Exposure Dysregulates Insulin Secretion in Male and Female Mice},
journal = {Diabetes},
year = {2025},
volume = {74},
number = {4},
pages = {528--543},
doi = {10.2337/db24-0419}
}
EUVIMED